stockrow
Friday 6 November 2026
Export PRCT’s income statement to Excel — free account
PROCEPT BioRobotics Corporation
PRCT Healthcare Medical Devices
PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024.
- Revenue
- +18.0%
- EPS
- −21.1%
- Free cash flow
- −1.57%
- Total debt
- +0.39%
Quarter to September 2026, against a year earlier
20.75
0.48
+2.37%
Follow PRCT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 4 | 4 |
| (24.89%) | (27.81%) | (30.24%) | (32.39%) | ||
| (18.34%) | (20.36%) | (22.12%) | (23.31%) | ||
ROIC |
(49.56%) | (44.34%) | (43.57%) | (45.60%) | |
Return on Tangible Assets |
(23.03%) | (25.87%) | (28.29%) | (30.71%) | |
Average Days of Receivables |
98.97 | 109.25 | 116.43 | 108.82 | |
Free Cash Flow per Share |
(1.05) | (1.43) | (1.49) | (1.48) | |
Free Cash Flow |
(58.34) | (80.57) | (84.92) | (85.07) | |
Capital Expenditures |
(9.36) | (10.43) | (10.58) | (8.38) | |
| Other line items | |||||
Cash ROIC |
(8.29%) | (12.49%) | (13.70%) | (14.20%) | |
Accounts Receivable Turnover |
3.69 | 3.67 | 3.58 | 3.72 | |
Accounts Payable Turnover |
8.19 | 6.89 | 8.99 | 8.95 | |
Inventory Turnover |
1.76 | 1.66 | 1.68 | 1.68 | |
Average Days of Payables |
56.42 | 59.31 | 45.57 | 49.01 | |
Days of Inventory on Hand |
230.74 | 243.95 | 233.04 | 238.64 | |
Tax Rate |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
23.14% | 23.71% | 23.36% | 22.89% | |
Selling, General and Administrative Expense of Revenue |
74.28% | 74.12% | 74.72% | 75.38% | |
Share Based Compensation of Revenue |
15.45% | 15.70% | 15.69% | 15.19% | |
Interest Coverage |
(28.96) | (30.91) | (32.88) | (34.71) | |
Operating CF/Net income |
0.51 | 0.68 | 0.68 | 0.67 | |
Depreciation/Fixed assets |
0.21 | 0.21 | 0.22 | 0.26 | |
Capex/Depreciation |
(1.46) | (1.57) | (1.50) | (1.05) | |
Revenue per Share |
5.55 | 5.70 | 5.91 | 6.15 | |
Operating CF per Share |
(0.88) | (1.24) | (1.30) | (1.34) | |
Capex per Share |
(0.17) | (0.18) | (0.19) | (0.15) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.02 |
Columns are period end dates · fundamentals updated 4 Nov 2026